SCHEMBL4489322

SCHEMBL4489322

Cc1ccc(-c2c3ccccc3nn2Cc2ccccc2C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 6/20 0.46
NR1H3 Q13133 6/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
P2RY14 Q15391 1/20 0.44
NR1I2 O75469 1/20 0.42
NR3C1 P04150 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
NPC1 O15118 1/20 0.41
GALR3 O60755 1/20 0.41
NR2F2 P24468 1/20 0.41
RAB9A P51151 1/20 0.41
POLB P06746 2/20 0.40
LMNA P02545 1/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TP53 P04637 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27669283 0.87 NR1H2 (0.42) NR1H2NR1H3SMN1; SMN2NR1I2NR3C1
SCHEMBL4487606 0.86 NR1H2 (0.56) NR1H2NR1H3SMN1; SMN2P2RY14NR1I2
SCHEMBL4479319 0.84 SMN1; SMN2 (0.52) NR1H2NR1H3SMN1; SMN2CYP11B1CYP11B2
SCHEMBL4494497 0.82 ALDH1A1 (0.53) NR1H2NR1H3SMN1; SMN2NPC1RAB9A
SCHEMBL5245419 0.82 NR1H2 (0.69) NR1H2NR1H3NR1I2NR3C1MEN1
SCHEMBL4482187 0.79 NR1H2 (0.52) NR1H2NR1H3SMN1; SMN2NPC1RAB9A
SCHEMBL27669279 0.78 CYP1A2 (0.49) NR1H2NR1H3SMN1; SMN2CYP11B1CYP11B2
SCHEMBL4476028 0.76 CHRM1 (0.50) SMN1; SMN2RAB9APOLBLMNAMEN1
SCHEMBL4478557 0.76 HTT (0.56) SMN1; SMN2NPC1RAB9APOLBLMNA
SCHEMBL4476567 0.75 MAPT (0.58) NR1H2NR1H3SMN1; SMN2P2RY14NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514465-B2 Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-04-07 US disclosed
EP-1659115-A1 Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents Yung Shin Pharm. Ind. Co., Ltd. (TW) 2006-05-24 EP disclosed
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents FLT4, FLT1, KDR NR1H2 3809/4885NR1H3 3609/4885SMN1; SMN2 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.